SA News • Today, 4:04 PM
- Bayer's revenue is up in all of its divisions; net income is up 12.7%.
- I forecasted ongoing growth, especially in Pharma and CropSciences. I have been correct so far.
- I remain with my original conclusion: Bayer is an attractive investment.
- Bayer AG offers great fundamentals.
- Bayer AG yields 2% right now, dividend has been increased constantly over the past.
- Multiples are higher than those of peers, might not be the best time to buy right now.
There are no Transcripts on BAYZF.
Today, 4:04 PM
- Sources close to the matter say Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) is exploring the sale of its diabetes device business as it focuses on higher growth areas. The company is supposedly working with Credit Suisse on the potential deal. Observers believe the unit could fetch between €1B - 2B ($2.5B).
- Bayer also intends to jettison its plastics business.
Wed, Oct. 29, 2:48 PM
- Bayer (OTCPK:BAYZF, OTCPK:BAYRY) says its crop science unit agrees to acquire certain crop protection and land-management assets from DuPont (DD -1.7%) for an unspecified amount.
- The deal will enable Bayer to offer a broad range of products for weed control for farming, and will provide access to the growing forestry and range and pasture business segments in North America.
- DuPont will continue to sell its land management products outside of the five countries where the assets are located: the U.S., Canada, Mexico, Australia and New Zealand.
Wed, Oct. 22, 2:43 PM
- P-E firms are coveting Bayer's (OTCPK:BAYZF, OTCPK:BAYRY) €10B ($12.7B) plastics business, hoping to sway the German drugmaker from its plan to list the division in an IPO, Reuters reports.
- Advent, Carlyle and KKR reportedly are among P-E firms, as well as sovereign wealth funds and pension funds, considering MaterialScience after Bayer said in September that it planned to spin off the division through a stock listing.
- Market conditions for IPOs have weakened in recent weeks, forcing a number of companies to pull their listings and potentially heightening the attractiveness of a sale to P-E firms.
Tue, Oct. 21, 9:08 AM
- Privately-held Boehringer Ingelheim commences patient enrollment in a Phase 3 clinical trial evaluating the safety and efficacy of nintedanib in patients with colorectal cancer refractory to standard treatments. The double-blind randomized, placebo-controlled study will enroll more that 750 patients at 150 sites worldwide.
- Nintedanib (trade name Ofev) is a small molecule tyrosine kinase inhibitor that was recently approved by the FDA for idiopathic pulmonary fibrosis.
- CRC-related tickers: (NASDAQ:GILD) (NYSE:LLY) (NASDAQ:MGNX) (OTCPK:BAYRY) (OTCPK:BAYZF) (NASDAQ:AMGN) (OTC:MKGAF) (NYSE:BMY) (NASDAQ:ONXX) (NASDAQ:IMMU) (NASDAQ:ONCY) (NASDAQ:ARQL) (NYSE:SNY) (OTCQB:SNYNF) (NASDAQ:REGN)
Tue, Oct. 14, 3:44 PM
- Compugen (CGEN -0.4%) achieves the second preclinical milestone for one of the two checkpoint protein candidates in its previously-announced collaboration with Bayer HealthCare (OTCPK:BAYRY +0.2%)(OTCPK:BAYZF -0.4%). The event triggers a $6M payment from Bayer out of the $30M potential milestone payments related to the joint preclinical research for the two programs.
- The potential $30M in milestones are in addition to the $500M that Compugen can earn if the two programs are successful.
Wed, Oct. 8, 12:35 PM
- The FDA accepts and grants priority review of Roche unit Genentech's (OTCQX:RHHBY +0.1%) supplemental Biologics License Application (sBLA) of Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy. The PDUFA date is February 6, 2015.
- Lucentis is currently cleared for the treatment of wet age-related macular degeneration, macular edema following retinal vein occlusion and diabetic macular edema.
- Related tickers: (REGN -0.4%)(AGN +1.1%)(ALIM +1%)(OTCPK:BAYRY +0.2%)(OTCPK:BAYZF)(PSDV -4.8%)
Mon, Oct. 6, 1:55 PM
- Privately-held Danbury, CT-based Perosphere enters into a third collaboration agreement with Daiichi Sankyo to study PER977, Perosphere's investigational anticoagulant reversal agent, in Phase 3 trials with edoxaban, Daiichi's investigational oral, once-daily factor Xa-inhibitor.
- In Phase 1 and 2 studies, PER977 showed that it directly binds to heparin as well as circulating direct factor Xa- and IIa-inhibitors reversing their anticoagulant effect. PER977 does not bind to blood coagulation factors or other blood proteins. In healthy volunteers, it reverses anticoagulant activity after a single IV dose of 100 mg - 300 mg and does not require an extended infusion in order to maintain the reversal.
- Under the terms of the agreement, Perosphere will seek FDA and EMA approval of PER977 to reverse anticoagulant activity of edoxaban and commercialize PER977 in the U.S. and EU. It retains full worldwide commercial rights to PER977. Perosphere will receive an upfront payment from Daiichi Sankyo as well as clinical development-related milestones. It plans to submit an NDA to the FDA by June 2015.
- Related tickers: (JNJ -0.4%)(OTCPK:BAYRY -0.4%)(OTCPK:BAYZF +0.1%)(PFE -0.3%)(BAX)(BMY -0.3%)(ISIS -1.9%)(PTLA)(AZN -0.1%)(MRK -0.6%)
Mon, Sep. 22, 7:46 AM
- The Japanese Ministry of Health, Labour and Welfare approves the use of Regeneron Pharmaceuticals' (NASDAQ:REGN) Eylea (aflibercept) injection for the treatment of choroidal neovascularization (myopic CNV).
- Eylea is already approved for sale for neovascular age-related macular degeneration (wet AMD) and macular edema secondary to central vein occlusion (CRVO).
- Eylea is marketed in Japan by Bayer Healthcare's (OTCPK:BAYRY) (OTCPK:BAYZF) Japanese subsidiary Bayer Yakuhin, Ltd.
Thu, Sep. 18, 7:54 AM
- Following reports of a spin-off of its plastics business MaterialsScience, Bayer (OTCPK:BAYZF, OTCPK:BAYRY) has announced its plans to publicly list the unit.
- The move was approved by Bayer’s management board earlier this month and is expected to be considered by its supervisory board today.
- Bayer has not yet indicated to where or when it expects to list the shares of the division.
Wed, Sep. 17, 6:45 PM
- Bayer (OTCPK:BAYZF, OTCPK:BAYRY) plans to separate its plastics business, WSJ reports, a move that would further its shift away from its roots in chemicals and toward life sciences.
- Bayer could announce as soon as tomorrow a plan to shed the MaterialsScience unit, but the company reportedly has not decided what form the separation would ultimately take - an outright sale, IPO or spin off.
- The unit, which makes polycarbonate, polyurethane and other polymers had sales last year of €11.2B ($14.4B), down 2.2% Y/Y, and analysts have valued it at ~€10B, but in terms of growth, the business has underperformed Bayer's prescription drug and other life sciences operations.
Thu, Sep. 4, 7:51 AM
- Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) subsidiary Bayer Yakuhin, Ltd. submits a marketing authorization application to the Japanese Ministry of Health, Labour and Welfare for Eylea (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO).
- Eylea is currently approved for use in Japan for neovascular (wet) age-related macular degeneration and macular edema secondary to central retinal vein occlusion.
- Marketing applications for Eylea for the treatment of choroidal neovascularization secondary to pathologic myopia and for the treatment of diabetic macular edema are currently under regulatory review.
- Related ticker: (REGN +0.7%)
Fri, Aug. 29, 9:05 AM
- People familiar with the situation say that the Belgian OTC drug maker Omega Pharma NV has attracted interest from a number of pharmaceutical companies including Perrigo (NYSE:PRGO), Boehringer Ingelheim, Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) and Sanofi (NYSE:SNY) (OTCQB:SNYNF).
- The tab for acquiring the business could be as high as 4B euros ($5.3B).
Mon, Aug. 25, 10:18 AM
- The FDA approves Iroko Pharmaceuticals' Zorvolex (diclofenac) for the management of osteoarthritis pain. The agency cleared the NSAID for the treatment of mild-to-moderate pain in adults in October 2013.
- Related tickers: (PFE +0.1%) (MRK +0.9%) (OTCPK:BAYZF) (OTCPK:BAYRY +1.2%) (OTCQX:RHHBY +0.6%) (TEVA -0.5%) (MYL +0.8%) (PRGO -0.1%) (GSK +0.8%)
Mon, Aug. 11, 7:12 AM
- The European Commission approves Regeneron Pharmaceuticals' (NASDAQ:REGN) Eylea (aflibercept) for the treatment of visual impairment caused by diabetic macular edema (DME). The new indication complements its current approvals for wet age-related macular degeneration (AMD) and macular edema following central retinal vein occulsion (CRVO).
- Partner Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) plans to launch Eyea for DME this quarter.
Fri, Jul. 25, 11:48 AM
- Bayer HealthCare Pharmaceuticals (OTCPK:BAYRY -2.4%) (OTCPK:BAYZF -1.7%) and development partner Onyx Pharmaceuticals (AMGN -0.3%) report that the 537-patient Phase 3 clinical trial evaluating the safety and efficacy of Nexavar (sorafenib) plus capecitabine for the treatment of advanced breast cancer failed to achieve its primary endpoint of improving progression-free survival (PFS). Nexavar is currently approved in over 100 countries for other cancers.
- The companies are evaluating Nexavar in a variety of different cancers. Bayer has exclusive marketing rights to the product ex. U.S. and Japan. They co-promote it in America and share profits globally.
Mon, Jul. 21, 8:56 AM
- German private equity firm Aurelius has agreed to buy Reckitt Benckiser's (OTCPK:RBGLY) Scholl shoe business. The company is expecting the brand to expand internationally and maintain growth.
- Aurelius will acquire the international rights to the business, except for North and South America, which will go to Bayer (OTCPK:BAYRY) as part of its $14B purchase of Merck (NYSE:MRK).
- The deal is expected to close in the third quarter of 2014.
BAYZF vs. ETF Alternatives
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. At the same time Bayer creates value through innovation, growth and improved earning power. <br /> <br />Bayer HealthCare AG researches, develops, manufactures and markets... More
Other News & PR